Articles from Labcorp

Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans.

Labcorp (NYSELH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.

Labcorp (NYSELH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial management and commercialization solutions to pharmaceutical and biotechnology organizations around the world.

Labcorp (NYSELH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp (NYSELH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.

Labcorp (NYSELH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023. Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp’s chairman and CEO Adam Schechter. At the time of the spin-off, Mr. Pike will serve as the chief executive officer and chairman of the Board of the independent, publicly listed company. In the coming months, Labcorp will announce the Board of Directors of the new company, including its lead independent director.

Labcorp (NYSELH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).

Labcorp (NYSELH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company’s global central laboratory capabilities.

Labcorp (NYSELH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, Nov. 8, at 1:25 p.m. PT.

Labcorp (NYSELH), a leading global life sciences company, today announced results for the third quarter ended Sept. 30, 2022, and updated full-year guidance.

Labcorp (NYSELH), a leading global life sciences company, today announced that Kirsten Kliphouse, president of Americas, Google Cloud, has joined its Board of Directors as an independent member.

Labcorp (NYSELH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on Dec. 9, 2022, to stockholders of record as of the close of business on Nov. 17, 2022.

Labcorp (NYSELH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States.

Labcorp (NYSELH), a leading global life sciences company, will release its financial results for the third quarter of 2022 before the market opens on Thursday, Oct. 27, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp (NYSELH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Tuesday, Sept. 13, at 9:05 a.m. ET.

Labcorp (NYSELH), a leading global life sciences company, today announced that it has closed its acquisition of RWJBarnabas Health’s outreach laboratory business and select related assets. RWJBarnabas Health is New Jersey’s largest academic health system.

Labcorp (NYSELH), a leading global life sciences company, today announced results for the second quarter ended June 30, 2022, and updated full-year guidance.

Labcorp (NYSELH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction. The planned spin-off will result in two independent, publicly traded companies, each poised for strong, sustainable growth:

Labcorp (NYSELH), a leading global life sciences company, today announced that it scored 100, the highest score possible, on the 2022 Disability Equality Index® (DEI), a comprehensive benchmarking tool for measuring disability inclusion in the workplace. The DEI, a joint initiative by Disability:IN® and the American Association of People with Disabilities (AAPD), exists to help businesses make a positive impact on the unemployment and underemployment of people with disabilities. With its score, Labcorp was also designated as a Best Place to Work for Disability Inclusion.

Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSELH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.

Labcorp® (NYSELH), a leading global life sciences company, today announced an expansion of its automated clinical trial kit production line in Mechelen, Belgium. Once completed, expansion will allow for clinical trial test kits to be fulfilled in Mechelen for more than 70 countries throughout Europe, the Middle East and Africa (EMEA). This is up from 27 countries in 2021. The company’s industry-leading central laboratory services unit is part of Labcorp Drug Development.

Labcorp (NYSELH), a leading global life sciences company, will release its financial results for the second quarter of 2022 before the market opens on Thursday, July 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp (NYSELH) (the Company), a leading global life sciences company, announced today that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 9, 2022, to stockholders of record as of the close of business on August 18, 2022.

Labcorp (NYSELH), a leading global life sciences company, today announced the launch of the first widely accessible test that provides direct evidence of neurodegeneration and neuronal injury. The new Neurofilament Light Chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients. Elevated NfL levels signal neuronal injury, whether from diseases like multiple sclerosis, Alzheimer’s and Parkinson’s, or from brain injury, such as with concussion.

Labcorp (NYSELH), a leading global life sciences company, today announced it has formed a strategic partnership with MD Anderson Cancer Center Foundation Spain, a non-profit organization whose objectives are to beat cancer and to increase accessibility of early phase oncology clinical trials. Through this collaboration, oncology clinical trials managed by Labcorp Drug Development will be prioritized and conducted at MD Anderson Cancer Center Foundation Spain, representing a new model for future trials.

Labcorp (NYSELH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox. This effort is part of the Administration’s commitment to quickly increase monkeypox testing access and capacity in every community during the ongoing outbreak.

Labcorp (NYSELH), a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.

Labcorp, a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions. Labcorp has signed Tigerlily’s #InclusionPledge for Black Women, joining other healthcare and life sciences companies in committing to eradicate barriers for women of color in accessing cancer care and research. Together, Tigerlily and Labcorp will work to end health disparities through the #InclusionPledge.

Labcorp® (NYSELH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs.

Labcorp (NYSELH), a leading global life sciences company, understands the important and growing role of precision medicine and is working to ensure more people have access to targeted and personalized treatments. As part of this effort, the company is announcing a new sponsored testing program aimed at helping advanced non-small cell lung (NSCLC) cancer patients and their physicians make informed treatment and care management decisions through comprehensive genomic insights.

Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSELH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue. LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. The test is available for use in both clinical trials and for the care and treatment of patients.

Labcorp (NYSELH), a leading global life sciences company, today announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.

Labcorp (NYSELH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 at 2:45 p.m. ET.

There is a new and convenient way for millions of individuals to assess whether they are at risk for developing diabetes. Labcorp (NYSELH), a leading global life sciences company, is making screening for diabetes easier with the launch of an at-home collection kit through Labcorp OnDemand™ that measures hemoglobin A1c (HbA1c) from a small blood sample.

Labcorp (NYSELH), a leading global life sciences company, and AtlantiCare, the largest health care organization in southern New Jersey, today announced that they have closed a transaction to expand their long-term strategic relationship. Labcorp will acquire select assets from AtlantiCare’s clinical outreach business, which serves the AtlantiCare Physician Group and Affiliated Physicians and their patients across southern New Jersey. The transaction is the latest in a series of new and expanded collaborations between Labcorp and health systems across the country, demonstrating the value that Labcorp brings to improve laboratory services and help enhance patient care.

Labcorp (NYSELH), a leading global life sciences company, today announced that its Annual Meeting of Shareholders will be webcast live beginning May 11, at 9:00 a.m. ET via the Labcorp Investor Relations website. An archived replay of the webcast will be available for one year.

Labcorp (NYSELH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2022, and updated full-year guidance.

Labcorp (NYSELH), a leading global life sciences company, today announced the launch of Getlabs for Labcorp, an innovative health care service that combines Labcorp’s diagnostic tests with Getlabs phlebotomy service to conveniently test consumers in the comfort of their own homes.

Labcorp (NYSELH), a leading global life sciences company, is collaborating with Xcell Biosciences, Inc. (Xcellbio), a leading developer of cell and gene therapy technologies, to advance critical work that helps clients effectively bring innovative cell and gene therapies to market.

Labcorp (NYSELH), a leading global life sciences company, announced today that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 9, 2022, to stockholders of record as of the close of business on May 19, 2022.

Labcorp (NYSELH), a leading global life sciences company, will release its financial results for the first quarter of 2022 before the market opens on Thursday, April 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp (NYSELH), a leading global life sciences company, is the first U.S. commercial laboratory to offer a new test developed by Immundiagnostik, Inc. to help individuals detect and quantify unintentional gluten consumption.

Labcorp (NYSELH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp’s existing liquid biopsy capabilities and expands Labcorp’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities, positioning Labcorp at the forefront of driving better patient outcomes in oncology.

Labcorp (NYSELH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2021, full-year 2022 guidance and longer-term outlook.

Labcorp (NYSELH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems. Through the expansive strategic collaboration, Labcorp will manage Ascension’s hospital-based laboratories in 10 states and purchase select assets of the health system’s outreach laboratory business. This long-term relationship will expand Labcorp’s clinical laboratory services in several states across the country while creating opportunities to enhance care across all clinical areas.

Labcorp (NYSELH), a leading global life sciences company, today announced the opening of a new diagnostics laboratory in South Bend, Indiana, allowing the company to enhance service levels and offerings to patients and physicians in South Bend and throughout the region.

Labcorp (NYSELH), a leading global life sciences company, today announced the launch of Labcorp OnDemand, an easy experience where individuals can purchase Labcorp OnDemand tests online, collect samples in the convenience of their home, or schedule test appointments at one of Labcorp’s 2,000 patient service centers (PSCs), including Labcorp at Walgreens locations. The OnDemand platform includes a suite of the company’s most popular tests, including its wellness, allergy, COVID-19, women’s health and fertility tests, to help individuals manage their health and make more informed decisions. A full list of tests available can be found by visiting www.OnDemand.Labcorp.com.

Labcorp (NYSELH), a leading global life sciences company, has been named to FORTUNE® magazine's 2022 list of the World’s Most Admired Companies, marking its fourth appearance on the list. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, asks top executives, directors and financial analysts to identify the companies with the strongest reputations across various industries.

Labcorp (NYSELH), a leading global life sciences company, today announced that it received a perfect score of 100% on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.

For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant. Labcorp (NYSELH), a leading global life sciences company, is making this possible by offering the Enhanced Liver Fibrosis (ELF™) test. Developed by Siemens Healthineers, the physician-ordered blood test helps assess the risk of disease progression in individuals—opening the door for improved outcomes. The test has been granted De Novo marketing authorization by the U.S. Food and Drug Administration.

Labcorp (NYSELH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp (NYSELH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11 at 4:30 p.m. (ET).

Labcorp (NYSELH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

Labcorp (NYSELH) (the Company), a leading global life sciences company, today announced actions that its Board of Directors (the Board) and management team have taken to enhance shareholder returns. This includes:

Labcorp (NYSELH), a leading global life sciences company, today announced that it has closed its acquisition of Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. The addition of Toxikon to Labcorp Drug Development bolsters Labcorp’s strong nonclinical development portfolio, and creates a strategic footprint for the company to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area.

Labcorp (NYSELH), a leading global life sciences company, and ConcertAI, LLC (ConcertAI), a leader in enterprise artificial intelligence (AI) and real-world data (RWD) solutions for life science companies and health care providers, today announced a collaboration to optimize precision oncology research. The companies will work together to launch clinical studies in ways that minimize the burden on physician practices, drive faster patient recruitment, maximize patient retention and ensure equitable access to research as a care option.

Labcorp (NYSELH), a global life sciences company, is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers (PSCs) nationwide for people without symptoms or known exposure. By mid-December, the company plans to further expand the COVID-19 PCR test collection service to over 1,000 locations.

Labcorp (NYSELH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering best-in-class nonclinical testing services. Once completed, the transaction will create a strategic footprint for Labcorp to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area and bolster its strong nonclinical development portfolio.

Labcorp (NYSELH), a leading global life sciences company, and the National Kidney Foundation (NKF), the largest patient organization dedicated to the prevention and treatment of kidney disease, announced their collaboration to promote the NKF Patient Network, the first national registry for chronic kidney disease (CKD) patients in the U.S. The NKF Patient Network will offer greater data and insights to physicians, as well as improved clinical trial access for patients with kidney disease.

Labcorp (NYSELH), a leading global life sciences company, today announced that members of its executive management team will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 1:00 p.m. ET.

Labcorp (NYSELH), a leading global life sciences company, today announced that Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, was recognized by Fierce Healthcare as one of its “2021 Women of Influence.” The award honors leaders who are defining the future of health care, have tangibly influenced the industry during the prior year and have a history of guiding others in their careers.

Labcorp (NYSELH), a leading life sciences company, today announced results for the third quarter ended September 30, 2021, and raised full-year guidance.

Labcorp (NYSELH), a leading global life sciences company, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with COVID-19 or if asked to be tested by a health care provider.

Labcorp (NYSELH), a leading global life sciences company, will release its financial results for the third quarter of 2021 before the market opens on Thursday, October 28, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp (NYSELH), a leading global life sciences company, today announced that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay.

Labcorp (NYSELH), a leading global life sciences company, today announced that members of its executive management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, Sept. 13 at 3:30 p.m. ET.

Labcorp (NYSELH), a leading global life sciences company, today announced it has increased the minimum hourly wage for United States (U.S.)-based, non-union employees to $15, effective September 2021.

Labcorp (NYSELH), a leading global life sciences company, and Community Clinical Oncology Research Network, LLC (CCORN), a leading research organization, today announced their collaboration to better understand the impact of disparities in precision medicine for people with cancer. Information gathered from a patient registry and biobank will be used to help design future cancer clinical trials in diverse populations.

Labcorp (NYSELH), a leading global life sciences company, today announced that it has acquired Ovia Health, a digital health platform used by millions of women seeking information and support with family planning, pregnancy and parenting.

Labcorp (NYSELH), a leading life sciences company, today announced results for the second quarter ended June 30, 2021, and raised full-year guidance.

Labcorp (NYSELH), a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp® (NYSELH), a leading global life sciences company, today announced the availability of therascreen® KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen.

Labcorp (NYSELH), a leading global life sciences company today announced that Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits are now in 6,000 Walgreens stores nationwide and through Walgreens collaborations with on-demand delivery services DoorDash and Instacart. The newly expanded availability and delivery option advances Walgreens and Labcorp’s efforts to increase COVID-19 testing access in communities across the U.S., especially in underserved areas.

Labcorp (NYSELH), a leading global life sciences company, today announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO®) Annual Meeting held June 4-8.

Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSELH) analysis of specimens from 39,086 individuals.